This is the authors' abstract. We don't add key points for this paper.
Aim: The purpose of this study was to optimize the dosing schedule of recombinant human erythropoietin (rhEPO) for perioperative autologous blood donation in patients undergoing total knee arthroplasty (TKA). Method: TKA patients receiving different dosing schedules of rhEPO were randomly divided into three groups. Group A patients were given 10,000 IU of subcutaneous rhEPO (1 ml) daily from preoperative day 5 to postoperative day 3 (9 doses); Group B patients were given subcutaneous normal saline daily from preoperative day 5 to day 3 and then subcutaneous rhEPO daily until postoperative day 3 (6 doses in total); Group C patients were given subcutaneous normal saline daily from preoperative day 5 to the day before surgery and then subcutaneous rhEPO daily from the surgery day to postoperative day 3 (4 doses). Results: A total of 180 TKA patients were included. On postoperative day 1 and 3, group A showed significantly higher Hb levels than group B and group C. The calculated blood loss was significantly greater in groups B and C than in group A on the day after surgery. Regarding total blood loss, groups B and C lost significantly more blood than group A. No case of allogeneic transfusion occurred during the trial in any of the three groups. Conclusions: A small dose of daily rhEPO from preoperative day 5 to postoperative day 3 could significantly increase perioperative autologous blood donation efficacy and slow the decline in postoperative Hb levels in TKA patients without causing extra complications.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: